JP2024521709A - ミトコンドリア関連障害の治療方法 - Google Patents

ミトコンドリア関連障害の治療方法 Download PDF

Info

Publication number
JP2024521709A
JP2024521709A JP2023571818A JP2023571818A JP2024521709A JP 2024521709 A JP2024521709 A JP 2024521709A JP 2023571818 A JP2023571818 A JP 2023571818A JP 2023571818 A JP2023571818 A JP 2023571818A JP 2024521709 A JP2024521709 A JP 2024521709A
Authority
JP
Japan
Prior art keywords
subject
methyl
dinitrophenol
disease
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521709A5 (https=
JPWO2022246039A5 (https=
Inventor
シャハリヤール カーン，
ダイアン ジョカスキー，
Original Assignee
リーバス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リーバス ファーマシューティカルズ， インコーポレイテッド filed Critical リーバス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024521709A publication Critical patent/JP2024521709A/ja
Publication of JP2024521709A5 publication Critical patent/JP2024521709A5/ja
Publication of JPWO2022246039A5 publication Critical patent/JPWO2022246039A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023571818A 2021-05-20 2022-05-19 ミトコンドリア関連障害の治療方法 Pending JP2024521709A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163191321P 2021-05-20 2021-05-20
US63/191,321 2021-05-20
US202163222841P 2021-07-16 2021-07-16
US63/222,841 2021-07-16
US202263307515P 2022-02-07 2022-02-07
US63/307,515 2022-02-07
PCT/US2022/029992 WO2022246039A1 (en) 2021-05-20 2022-05-19 Methods of treating mitochondria-related disorders

Publications (3)

Publication Number Publication Date
JP2024521709A true JP2024521709A (ja) 2024-06-04
JP2024521709A5 JP2024521709A5 (https=) 2025-05-27
JPWO2022246039A5 JPWO2022246039A5 (https=) 2025-05-27

Family

ID=82020295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571818A Pending JP2024521709A (ja) 2021-05-20 2022-05-19 ミトコンドリア関連障害の治療方法

Country Status (14)

Country Link
US (1) US20250177353A1 (https=)
EP (1) EP4340829A1 (https=)
JP (1) JP2024521709A (https=)
KR (1) KR20240021827A (https=)
AU (1) AU2022275935A1 (https=)
BR (1) BR112023024146A2 (https=)
CA (1) CA3219548A1 (https=)
CL (1) CL2023003441A1 (https=)
GE (1) GEAP202416398A (https=)
IL (1) IL308669A (https=)
JO (1) JOP20230298A1 (https=)
MX (1) MX2023013688A (https=)
TW (1) TW202313010A (https=)
WO (1) WO2022246039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150759A1 (en) * 2022-02-07 2023-08-10 Rivus Pharmaceuticals, Inc. Methods of weight loss in a subject with elevated hba1c
TW202515545A (zh) * 2023-08-10 2025-04-16 大陸商深圳君聖泰生物技術有限公司 ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
EP4340829A1 (en) 2024-03-27
KR20240021827A (ko) 2024-02-19
CL2023003441A1 (es) 2024-05-10
JOP20230298A1 (ar) 2023-11-19
US20250177353A1 (en) 2025-06-05
TW202313010A (zh) 2023-04-01
WO2022246039A1 (en) 2022-11-24
AU2022275935A1 (en) 2023-12-07
BR112023024146A2 (pt) 2024-01-30
CA3219548A1 (en) 2022-11-24
MX2023013688A (es) 2024-02-27
GEAP202416398A (en) 2024-01-25
IL308669A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
Zambrowicz et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes
US20210186990A1 (en) Methods and compositions for treating various disorders
KR20220070057A (ko) 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
JPH04507091A (ja) 体重減量医薬組成物
JP2024521709A (ja) ミトコンドリア関連障害の治療方法
JP2024529452A (ja) 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン
TWI866427B (zh) 雌激素受體降解劑之給藥方案
JP2024523945A (ja) 血糖値の管理方法ならびに糖尿病及び関連状態の治療
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
TW201215392A (en) Use of ranolazine for treating pulmonary hypertension
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
Kaul et al. A prospective, multicentre, single arm clinical study to evaluate the effect of saroglitazar on non high-density lipoprotein cholesterol in patients with diabetic dyslipidemia inadequately controlled with diet, exercise, and statin-the GLIDDER study
JP2026506102A (ja) 疼痛緩和に有用なレジメンおよび組成物
CN117881399A (zh) 治疗粒线体相关病症的方法
WO2019099509A1 (en) Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
US20250134865A1 (en) Methods of weight loss in a subject with elevated hba1c
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
CN118922187A (zh) 体重减轻和保持骨骼肌量的方法
KR20260055436A (ko) 심부전 치료용 화합물 azd5462
TW202525272A (zh) 治療心臟衰竭之方法
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
TW202444359A (zh) 用於向患有肝損傷的患者施用帕妥索汀的組合物和方法
Lipska et al. Cardiovascular risk-benefit ratio of thiazolidinediones
Philpott WINTER is coming! Pharmacists are a prime source of advice on treating common winter ailments such as cough and cold symptoms.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250519